Analyst Ratings for [SVRA] Savara, Inc.

8/15/25	Upgrades	Neutral Buy	X
SVRA Savara H.C. Wainwright
$5
5/29/25	Downgrades	Buy Neutral	X
SVRA Savara H.C. Wainwright
$2
12/20/24	Initiated	Overweight	X
SVRA Savara Wells Fargo
$8
11/13/24	Downgrades	Outperform In-line	X
SVRA Savara Evercore ISI
$7 $5
2/15/24	Initiated	Mkt Outperform	X
SVRA Savara JMP Securities
$8
11/7/23	Initiated	Buy	X
SVRA Savara Guggenheim
$7
5/16/23	Upgrades	Hold Buy	X
SVRA Savara Jefferies
$2 $4
3/31/23	Downgrades	Buy Hold	X
SVRA Savara Jefferies
$2
3/16/21	Initiated	Overweight	X
SVRA Savara Piper Sandler
$7
3/15/21	Initiated	Outperform	X
SVRA Savara Oppenheimer
$4
6/13/19	Reiterated	Buy	X
SVRA Savara H.C. Wainwright
$22 $6
6/13/19	Downgrades	Mkt Outperform Mkt Perform	X
SVRA Savara JMP Securities
6/13/19	Downgrades	Buy Neutral	X
SVRA Savara Ladenburg Thalmann
$21 $3
8/13/18	Resumed	Neutral	X
SVRA Savara ROTH Capital
$12

SVRA Savara, Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.